Abstract

Photodynamic therapy (PDT) mostly relies on the generation of singlet oxygen, via the excitation of a photosensitizer, so that target tumor cells can be destroyed. PDT can be applied in the settings of several malignant diseases. In fact, the earliest preclinical applications date back to 1900’s. Dougherty reported the treatment of skin tumors by PDT in 1978. Several further studies around 1980 demonstrated the effectiveness of PDT. Thus, the technique has attracted the attention of numerous researchers since then. Hematoporphyrin derivative received the FDA approval as a clinical application of PDT in 1995. We have indeed witnessed a considerable progress in the field over the last century. Given the fact that PDT has a favorable adverse event profile and can enhance anti-tumor immune responses as well as demonstrating minimally invasive characteristics, it is disappointing that PDT is not broadly utilized in the clinical setting for the treatment of malignant and/or non-malignant diseases. Several issues still hinder the development of PDT, such as those related with light, tissue oxygenation and inherent properties of the photosensitizers. Various photosensitizers have been designed/synthesized in order to overcome the limitations. In this Review, we provide a general overview of the mechanisms of action in terms of PDT in cancer, including the effects on immune system and vasculature as well as mechanisms related with tumor cell destruction. We will also briefly mention the application of PDT for non-malignant diseases. The current limitations of PDT utilization in cancer will be reviewed, since identifying problems associated with design/synthesis of photosensitizers as well as application of light and tissue oxygenation might pave the way for more effective PDT approaches. Furthermore, novel promising approaches to improve outcome in PDT such as selectivity, bioengineering, subcellular/organelle targeting, etc. will also be discussed in detail, since the potential of pioneering and exceptional approaches that aim to overcome the limitations and reveal the full potential of PDT in terms of clinical translation are undoubtedly exciting. A better understanding of novel concepts in the field (e.g. enhanced, two-stage, fractional PDT) will most likely prove to be very useful for pursuing and improving effective PDT strategies.

Highlights

  • Photodynamic therapy (PDT) is a therapeutic modality for specific malignant as well as non-malignant [e.g. age related macular degeneration (AMD), psoriasis] and premalignant conditions (Brown et al, 2004; Castano et al, 2006b)

  • The earliest preclinical applications of PDT were published more than a century ago and Photofrin received the Food and Drug Administration (FDA) approval in 1995, it is disappointing that PDT is not broadly utilized in the clinical setting for the treatment of malignant and/or non-malignant diseases

  • Several issues still hinder the development of PDT, such as limitations related with light, tissue oxygenation and inherent properties of the PSs

Read more

Summary

INTRODUCTION

Photodynamic therapy (PDT) is a therapeutic modality for specific malignant (e.g. gastrointestinal, skin, head and neck, and gynecological cancers) as well as non-malignant [e.g. age related macular degeneration (AMD), psoriasis] and premalignant (e.g. actinic keratosis) conditions (Brown et al, 2004; Castano et al, 2006b). The mechanisms of action depend on the generation of singlet oxygen (1O2), preferentially with high yield, through the excitation of a particular photosensitizer (PS), which transfers its excited energy to the molecular oxygen in tumor tissues via triplet state manifold. Second generation of PSs [e.g. chlorins, benzoporphyrin derivatives, texaphyrins, phthalocyanines and natural products such as hypericin and protoporphyrin IX (PpIX)] were designed in order to overcome the limitations of HpD. These second generation PSs have been used in cardiovascular and ophthalmological diseases (Rockson et al, 2000; Sivaprasad and Hykin, 2006). Novel promising approaches in terms of PDT will be reviewed, since the potential of pioneering approaches in order to overcome such limitations of PDT are truly exciting

MECHANISMS OF ACTION
Effects of Photodynamic Therapy on Tumors
CURRENT LIMITATIONS OF PHOTODYNAMIC THERAPY UTILIZATION IN CANCER
Overcoming Problems Related With Light and Drug Dose in Photodynamic Therapy
Selectivity of Photodynamic Therapy
Subcellular Targeting in Photodynamic Therapy
Findings
CONCLUDING REMARKS
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call